COMBINATION OF CHEMOTHERAPY AND HORMONE-THERAPY IN ADVANCED BREAST-CANCER

被引:0
|
作者
MERKLE, E [1 ]
BAR, I [1 ]
HENKE, A [1 ]
BUHNER, M [1 ]
WILDT, L [1 ]
MARTUS, P [1 ]
LANG, N [1 ]
机构
[1] UNIV ERLANGEN NURNBERG,INST MED STAT & DOKUMENTAT,W-8520 ERLANGEN,GERMANY
关键词
ADVANCED BREAST CANCER; COMBINED THERAPY; DECAPEPTYL(R); RESPONSE RATE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In a prospective study at the Department of Obstetrics and Gynaecology, University of Erlangen, patients with advanced breast carcinoma were treated with a combination of chemotherapy and hormone therapy. Patients received one injection of Decapeptyl(R) in a 28 days interval. At day 12 and 13 of the treatment cycle 40 mug of ethinylestradiol were applicated followed by intravenous chemotherapy with 500 mg/m2 fluorouracil, 10 mg/m2 mitoxantrone and 500 mg/m2 cyclophosphamide took place on day 14. 39 patients were integrated in this study. All of these patients were evaluable regarding the side-effects and 36 patients concerning the response rate. In case of response after 6 cycles the interval between the chemotherapy was prolonged to 6 weeks and the Decapeptyl(R) injections remained in a 4 weeks interval. 15 patients received this combined therapy as a first-line therapy, 24 patients as a second-line therapy or third-line therapy. 2 patients had a complete remission, 14 patients had a partial remission. The objective response rate (CR+PR) was therefore 44 %. In 8 patients the response was classified as no change, consequently the total response rate (CR + PR + NC) was 67 %. 12 patients showed a progression (33 %), 2 patients with several previous treatments suffered an early progress. 3 patients did not finish the therapy. The median response duration was 9 months and the median follow up time until now is 13 months; 24 patients died. Therapy related side-effects were tolerable. As the most frequent side-effect bone marrow suppression were observed. Subjective, for the patients most inconvenient side-effects like nausea, vometing, and alopecia seldomly appeared. The combination of chemotherapy and hormone therapy achieved with a good toleration response rates, which are compatible to international standards of chemotherapy. The exspectations to achieve a better remission rate by a combination of chemotherapy and hormone therapy rather than chemotherapy alone were not fulfilled in this studie.
引用
收藏
页码:220 / 223
页数:4
相关论文
共 50 条
  • [1] THE ROLE OF CISPLATIN IN CHEMOTHERAPY OF ADVANCED BREAST-CANCER
    JURGA, L
    MISUROVA, E
    KOVAC, V
    SEVCIKOVA, L
    NEOPLASMA, 1994, 41 (06) : 347 - 352
  • [2] COMBINATION CHEMOTHERAPY WITH EPIRUBICIN AND MITOMYCIN-C AS FIRST-LINE TREATMENT IN ADVANCED BREAST-CANCER
    PACINI, P
    TUCCI, E
    ALGERI, R
    RINALDINI, M
    GUARNIERI, A
    VALZELLI, S
    NERI, B
    EUROPEAN JOURNAL OF CANCER, 1994, 30A (04) : 460 - 463
  • [3] HOW TO IMPROVE CYTOTOXIC THERAPY IN ADVANCED BREAST-CANCER
    BASTHOLT, L
    MOURIDSEN, HT
    ACTA ONCOLOGICA, 1990, 29 (03) : 349 - 355
  • [4] PREDICTION OF HORMONE RESPONSIVENESS BY MAMMOGRAPHIC PARENCHYMAL PATTERN IN ADVANCED PRIMARY BREAST-CANCER
    NIELSEN, NSM
    ANDERSEN, J
    POULSEN, HS
    MATHIESSEN, O
    BREAST CANCER RESEARCH AND TREATMENT, 1992, 23 (03) : 219 - 222
  • [5] 5-FLUOROURACIL, EPIRUBICIN AND CYCLOPHOSPHAMIDE (FEC COMBINATION) IN ADVANCED BREAST-CANCER
    ZAMAGNI, C
    MARTONI, A
    ERCOLINO, L
    BARONI, M
    TANNEBERGER, S
    PANNUTI, F
    JOURNAL OF CHEMOTHERAPY, 1991, 3 (02) : 126 - 129
  • [6] EFFECTS OF CONTINUOUS VINDESINE ADMINISTRATION OF ADVANCED BREAST-CANCER RESISTANT TO CHEMOTHERAPY INCLUDING ADRIAMYCIN
    ADACHI, I
    WATANABE, T
    SUZUKI, M
    TSUCHIHASHI, T
    YIN, DF
    YAMAGUCHI, K
    ABE, K
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1991, 21 (03) : 180 - 187
  • [7] Changing Concepts of Hormone Receptor-Positive Advanced Breast Cancer Therapy
    Chlebowski, Rowan T.
    CLINICAL BREAST CANCER, 2013, 13 (03) : 159 - 166
  • [8] EFFECTIVE 2ND LINE CHEMOTHERAPY OF ADVANCED BREAST-CANCER WITH NAVELBINE AND MITOMYCIN-C
    SCHEITHAUER, W
    KORNEK, G
    HAIDER, K
    KWASNY, W
    SCHENK, T
    PIRKER, R
    DEPISCH, D
    BREAST CANCER RESEARCH AND TREATMENT, 1993, 26 (01) : 49 - 53
  • [9] Multikinase inhibitor in combination with chemotherapy in the treatment of advanced breast cancer-a meta-analysis
    Zeng, Qi
    Tan, Qi-Xing
    Qin, Qing-Hong
    Wei, Chang-Yuan
    Yang, Wei-Ping
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (06): : 10404 - 10413
  • [10] TAMOXIFEN AND ALPHA-INTERFERON IN ADVANCED BREAST-CANCER
    MIGLIETTA, L
    REPETTO, L
    GARDIN, G
    AMOROSO, D
    GIUDICI, S
    NASO, C
    MERLINI, L
    QUEIROLO, P
    CAMPORA, E
    PRONZATO, P
    ROSSO, R
    JOURNAL OF CHEMOTHERAPY, 1991, 3 (06) : 383 - 386